Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Oncol Pharm Pract ; 17(3): 288-91, 2011 Sep.
Article in English | MEDLINE | ID: mdl-20926454

ABSTRACT

Capecitabine is now-a-days rapidly replacing 5-Fluorouracil in daily clinical practice. Neurologic toxicity during a treatment with fluoropyrimidines, as 5-fluorouracil, represents a well-known side-effect, largely described in literature. Central nervous system (CNS) toxicity, mainly encephalopathy with or without seizures, occurs occasionally even when conventional doses are used. CNS toxicity incidence increases markedly when the blood-brain barrier is either overwhelmed or bypassed (Hildebrand J. Neurological complications of cancer chemotherapy. Curr Opin Oncol 2006; 18: 321-324). Peripheral nervous system (PNS) toxicity is more common because proximal and distal extremities of the peripheral nerves are not protected by a blood-brain like barrier and peripheral neuropathy remains a major limiting factor for the administration of conventional doses of several agents (Saif W, Wood TE, McGee PJ and Diasio RB. Peripheral neuropathy associated with capecitabine, Anticancer Drugs 2004;15: 767-771). Capecitabine is a prodrug of 5-fluorouracil, more easily administered by mouth; its transformation in 5-fluorouracil is performed in the liver. There are only a few reports on the toxic neurological side-effects of capecitabine. We describe in our report a rare case of toxic encephalopathy in a 82-year-old female, with a brief review of literature. In the literature reviewed, we found 12 neurologic episodes due to capecitabine lasting between a few days till some months. All clinical symptoms of the cases described in literature, obtained a complete regression with the discontinuation of capecitabine. A relation was not found with dihydropyrimidine dehydrogenase (DPD) mutation, also if pharmacologic and pharmacogenetic assessment should be done for this drug, especially in old patients. Toxic encephalopathy represents a rare event during capecitabine treatment and on the bases of the data found, is fairly managed in the clinical setting. The knowledge of the natural history of the toxic effect allows the use of the drug also in old patients.


Subject(s)
Adenocarcinoma/drug therapy , Antimetabolites, Antineoplastic/adverse effects , Colorectal Neoplasms/drug therapy , Deoxycytidine/analogs & derivatives , Fluorouracil/analogs & derivatives , Neurotoxicity Syndromes/etiology , Adenocarcinoma/secondary , Age Factors , Aged, 80 and over , Bone Neoplasms/secondary , Capecitabine , Colorectal Neoplasms/pathology , Deoxycytidine/adverse effects , Fatal Outcome , Female , Fluorouracil/adverse effects , Humans , Neurotoxicity Syndromes/diagnosis , Patient Selection , Risk Assessment , Risk Factors
2.
Herpes ; 13(3): 72-4, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17147911

ABSTRACT

A case of primary infection by human herpesvirus 6 (HHV-6) variant A in a 54-year-old woman, which occurred at the same time as the onset of encephalomyelitis, is reported. The correlation between the two events is discussed. It is speculated that, during the early phase of the infection, the HHV-6 spread to the central nervous system and triggered a pathogenic process that initially developed without symptoms. When the neurological disorders appeared, HHV-6 had already established a latent state: only the virus carried by infected blood cells was detected in the cerebrospinal fluid.


Subject(s)
Encephalomyelitis/virology , Herpesvirus 6, Human/classification , Herpesvirus 6, Human/isolation & purification , Roseolovirus Infections/complications , Cervical Vertebrae/diagnostic imaging , DNA, Viral/blood , DNA, Viral/cerebrospinal fluid , Encephalomyelitis/diagnostic imaging , Female , Genetic Variation , Herpesvirus 6, Human/genetics , Humans , Middle Aged , Radiography , Roseolovirus Infections/diagnostic imaging , Roseolovirus Infections/virology
SELECTION OF CITATIONS
SEARCH DETAIL
...